Mastery EAQ Ch. 34

A  Strong contractions

B  Decreased pain

C  Midline fundus

D  Softened cervix

A  Pulmonary embolism

B  Abnormal vaginal bleeding

C  Renal failure

D  Ovarian failure

A  Hirsutism, Bradycardia, Increased diuresis

B  Anxiety, Dizziness, Blurred vision

C  Blurred vision, Bradycardia, Increased diuresis

D  Hirsutism, Dizziness,, Increased diuresis

A  For at least 6 weeks, starting at the end of the antibiotic regimen

B  During the entire period the patient is taking the antibiotic

C  Until three throat cultures have been negative for the pathogen

D  For at least 1 month after starting the antibiotic

A  Megestrol

B  Alendronate

C  Estradiol

D  Methylergonovine

A  Protamine sulfate

B  Atropine

C  Epinephrine

D  Calcium gluconate

A  Obtain a prescription for terbutaline.

B  Obtain a prescription for indomethacin.

C  Decrease the drug dose immediately.

D  Request a prescription to give calcium gluconate.

A  Place the patient on her left side.

B  Administer phentolamine mesylate.

C  Immediately discontinue intravenous (IV) fluids.

D  Instruct the patient to bear down and push.

A  Monitor the patient for blurred vision. Administer it before placenta delivery. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

B  Monitor the patient for blurred vision. Monitor blood pressure during administration. Administer it before placenta delivery. Question the prescription if the patient has liver disease.

C  Administer it before placenta delivery. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

D  Monitor the patient for blurred vision. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

A  Pelvic inflammatory disease

B  Hypertension

C  Nausea and vomiting

D  Uterine atony

A  Temperature

B  Blood glucose

C  Blood pressure

D  Uterine contractions

A  Absence of cervical ripening at 42 weeks’ gestation

B  Vaginal bleeding at 38 weeks’ gestation

C  Radiographic confirmation of cephalopelvic disproportion

D  Ineffective contractions in a full-term pregnancy

A  Low fluid intake

B  Cigarette use

C  Use of herbal supplements

D  Current tricyclic antidepressant use

A  Fetal movement, Uterine hyperactivity, Complete blood cell count

B  Fetal heart rate, Fetal movement, The patient’s blood pressure and pulse

C  Uterine hyperactivity, Fetal heart rate, Complete blood cell count

D  The patient’s blood pressure and pulse, Complete blood cell count, Uterine hyperactivity

A  Denosumab

B  Calcitonin

C  Ibandronate

D  Tamoxifen

A  Ask the patient to include soy in her diet.

B  Advise the patient to engage in quiet activities.

C  Persuade the patient to start the therapy.

D  Inform the patient about the benefits and risks of the therapy.

A  “The treatment is likely to cause endometrial cancer.”

B  “You may need to stop smoking during the therapy.”

C  “The treatment should be started as soon as possible.”

D  “The therapy may cause thromboembolic events.”

A  Terbutaline

B  Ritodrine

C  Magnesium sulfate

D  Bed rest and hydration

A  Hypertension

B  Anticonvulsant therapy

C  Diabetes

D  Antibiotic therapy

A  Norethindrone and ethinyl estradiol

B  Male condom with spermicidal jelly

C  Medroxyprogesterone

D  Cervical cap with spermicidal jelly

A  Allergy to salmon

B  Current smoker

C  Joint pain

D  Breast cancer

A  “Replace the bisphosphonate with calcitonin.”

B  “Discontinue the calcium supplement.”

C  “Space the medications 1 to 2 hours apart.”

D  “Obtain a prescription for increasing the bisphosphonate dose.”

A  “Have tests for serum cholesterol.”

B  “Report missed menstrual periods.”

C  “Perform weight-bearing exercise.”

D  “Have a yearly mammogram.”

A  “Decreased Gn-RH suppresses the release of follicle-stimulating hormone.”

B  “Estrogen levels inhibit the release of follicle-stimulating hormone.”

C  “High progesterone levels inhibit the release of luteinizing hormone.”

D  “Surges of Gn-RH, follicle-stimulating hormone, and luteinizing hormone stimulate ovulation.”

A  “I am no longer experiencing painful intercourse.”

B  “I no longer experience hot flashes.”

C  “I have seen a great improvement in my sexual desire.”

D  “I have not experienced any uterine bleeding.”

A  Ferritin

B  Levothyroxine

C  Amoxicillin

D  Metformin

A  Contains estrogen, which stimulates bone reabsorption

B  Stimulates estrogen receptors on the bone to increase bone density

C  Promotes bone absorption of calcium

D  Inhibits osteoclast-mediated bone reabsorption

A  Warfarin, Cholestyramine

B  Levothyroxine, Multivitamin

C  Atenolol, Levothyroxine

D  Multivitamin, Atenolol

A  “I need to take this medication with food to prevent damage to my esophagus.”

B  “I will take the medication on an empty stomach and not lie down for 30 minutes.”

C  “I need to decrease my intake of dairy products to prevent hypercalcemia.”

D  “This medication will help relieve the bone pain I have from my osteoporosis.”

A  Hot flashes, Loss of appetite, Joint pain

B  Hot flashes, Vertigo, Loss of appetite

C  Chest pain, Hot flashes, Loss of appetite

D  Vertigo, Joint pain, Chest pain

A  To induce cervical ripening

B  To treat pelvic inflammatory disease

C  To terminate pregnancy

D  To treat gestational hypertension

A  Smoking heavily every day

B  Sedentary lifestyle

C  Consumption of saturated fats

D  Increased body mass index (BMI)

A  Monotherapy with a progestin increases breast cancer risk.

B  Unopposed estrogen increases the risk of endometrial cancer.

C  Estrogen monotherapy increases the risk of breast cancer.

D  Estradiol with progestin increases the risk of endometrial cancer.

A  Prostaglandin E

B  Clomiphene

C  Oxytocin

D  Terbutaline

A  Megestrol

B  Estropipate

C  Estrone

D  Medroxyprogesterone

A  Hot flashes

B  Brown discoloration of face

C  Yellow undertone to the skin

D  Loss of hair

A  Suggest the patient take aluminum hydroxide with the medication.

B  Monitor the patient’s blood pressure frequently.

C  Assess pulse oximetry continuously.

D  Administer acetaminophen as needed.

A  Oxytocin

B  Indomethacin

C  Dinoprostone

D  Clomiphene

A  Ethinyl estradiol

B  Clomiphene

C  Progesterone

D  Choriogonadotropin alfa

A  Uterine bleeding

B  Deep vein thrombosis

C  Weight loss

D  Dysmenorrhea

A  “Vaginal cancer is prevented by adding progestin to the regimen.”

B  “The progestin in the regimen will help prevent ovarian cancer.”

C  “The progestin in the regimen will help prevent breast cancer.”

D  “Endometrial cancer risk can be reduced by adding progestin.”

A  Diminished endometrial tissue proliferation

B  Inhibition of the release of gonadotropins

C  Elevated progesterone levels inhibiting the release of the luteinizing hormone

D  Interference with the proliferation of the fertilized ovum

A  Luteinizing hormone

B  Follicle-stimulating hormone

C  Antidiuretic hormone

D  Adrenocorticotropic hormone

A  Hypertension

B  Dysmenorrhea

C  Weight gain

D  Thrombophlebitis

A  Higher-pitched voice

B  Dry skin

C  Nausea

D  Weight loss

A  Postpartum hemorrhage

B  Termination of pregnancy

C  Premature labor

D  Accelerated labor

A  Esterified estrogens

B  Alendronate

C  Medroxyprogesterone

D  Megestrol

A  Phase 4

B  Phase 3

C  Phase 2

D  Phase 1

A  Biphasic

B  Monophasic

C  Triphasic

D  Extended-cycle

A  Follicle-stimulating hormone (FSH)

B  Luteinizing hormone (LH)

C  Luteotropic hormone

D  Interstitial cell-stimulating hormone

A  Indomethacin

B  Megestrol

C  Methylergonovine

D  Medroxyprogesterone acetate

A  Methylergonovine

B  Terbutaline

C  Oxytocin

D  Magnesium sulfate

A  Raloxifene

B  Megestrol

C  Methylergonovine

D  Clomiphene

A  Day 14

B  Day 3

C  Day 7

D  Day 21

A  Adrenocorticotropic hormone

B  Luteinizing hormone (LH)

C  Follicle-stimulating hormone (FSH)

D  Antidiuretic hormone

A  The patient is ready for delivery.

B  The contractions can be fatal to the patient.

C  The fetal heart rate is stable.

D  The patient’s blood pressure is stable.

A  Compliance with the fertility drugs

B  Presence of abnormal uterine bleeding

C  Current smoking status

D  Current use of medications for depression

A  Dementia, Ovarian cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

B  Dementia, Breast cancer, Ovarian cancer, Cardiovascular disease, Serious cardiovascular events

C  Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Ovarian cancer

D  Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events